These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8675554)

  • 1. Tibolone: prevention of bone loss in late postmenopausal women.
    Bjarnason NH; Bjarnason K; Haarbo J; Rosenquist C; Christiansen C
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2419-22. PubMed ID: 8675554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures.
    Pavlov PW; Ginsburg J; Kicovic PM; van der Schaaf DB; Prelevic G; Bennink HJ
    Gynecol Endocrinol; 1999 Aug; 13(4):230-7. PubMed ID: 10533157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.
    Gallagher JC; Baylink DJ; Freeman R; McClung M
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4717-26. PubMed ID: 11600531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
    Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
    Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
    Morris EP; Rymer J; Robinson J; Fogelman I
    Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women.
    Reginster JY; Agnusdei D; Gennari C; Kicovic PM
    Gynecol Endocrinol; 1999 Oct; 13(5):361-8. PubMed ID: 10599554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss.
    Rymer J; Robinson J; Fogelman I
    Osteoporos Int; 2001; 12(6):478-83. PubMed ID: 11446564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study.
    Berning B; Kuijk CV; Kuiper JW; Bennink HJ; Kicovic PM; Fauser BC
    Bone; 1996 Oct; 19(4):395-9. PubMed ID: 8894146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
    Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
    Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss.
    Roux C; Pelissier C; Fechtenbaum J; Loiseau-Peres S; Benhamou CL
    Osteoporos Int; 2002 Mar; 13(3):241-8. PubMed ID: 11991445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial.
    Zhang G; Qin L; Shi Y
    J Bone Miner Res; 2007 Jul; 22(7):1072-9. PubMed ID: 17419678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial.
    Beardsworth SA; Kearney CE; Purdie DW
    Br J Obstet Gynaecol; 1999 Jul; 106(7):678-83. PubMed ID: 10428524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.
    Jacobsen DE; Melis RJ; Verhaar HJ; Olde Rikkert MG
    J Am Med Dir Assoc; 2012 Feb; 13(2):189.e1-7. PubMed ID: 21741883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tibolone and its effects on bone: a review.
    Berning B; Bennink HJ; Fauser BC
    Climacteric; 2001 Jun; 4(2):120-36. PubMed ID: 11428176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Monteleone P; Benussi C; Bevilacqua G; Genazzani AR
    Gynecol Endocrinol; 2004 Jan; 18(1):9-16. PubMed ID: 15106359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in bone turnover during tibolone treatment.
    Riera-Espinoza G; Ramos J; Carvajal R; Belzares E; Stanbury G; Farías R; Valderrama I; Alvarez K; Riera-González G
    Maturitas; 2004 Feb; 47(2):83-90. PubMed ID: 14757266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.